Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Somnomed Limited ( (AU:SOM) ) has provided an update.
SomnoMed Limited announced a change in the director’s interest, with Amrita Singh Blickstead acquiring 600,000 zero exercise price options, increasing her total to 1,925,000 options. Additionally, the company plans to issue 1,000,000 options under the SomnoMed Employee Share Option Plan, contingent on shareholder approval, with a two-year expiry and a $0.65 exercise price, reflecting strategic incentives for key personnel.
The most recent analyst rating on (AU:SOM) stock is a Buy with a A$0.45 price target. To see the full list of analyst forecasts on Somnomed Limited stock, see the AU:SOM Stock Forecast page.
More about Somnomed Limited
SomnoMed Limited operates in the healthcare industry, specializing in the development and distribution of oral appliances for the treatment of sleep-related disorders, particularly obstructive sleep apnea. The company focuses on providing innovative solutions to improve sleep health and quality of life for patients globally.
Average Trading Volume: 67,993
Technical Sentiment Signal: Hold
Current Market Cap: A$141.6M
See more data about SOM stock on TipRanks’ Stock Analysis page.